In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| 8-K | 8-K | 10-K | 10-Q/A | 10-Q | 10-Q/A | 10-K | 10-Q/A |
Operating activities | | | | | | | | |
Net loss | | -7.7 | 46.2 | 45.6 | -53.4 | -4.7 | -56.1 | -53.7 |
|
Adjustments to reconcile to net loss to net cash used in operating activities | | | | | | | | |
Depreciation and amortization | | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
Share-based compensation | | 1.0 | 0.7 | 1.1 | 1.9 | 1.5 | 1.5 | 1.3 |
|
Beneficial conversion feature on convertible debenture | | | | | | | | |
Accretion of discount on convertible debenture | | | | | | | | |
Change in fair value of warrants liability | | 0.2 | -11.1 | -10.5 | -0.3 | -4.8 | 0.9 | -0.6 |
Change in fair value of derivative liability | | 0.2 | -11.3 | -10.5 | -0.2 | -4.8 | 0.9 | -0.6 |
Loss on disposal of asset | | | | | | | 0.0 | 0.0 |
Gain on extinguishment of PPP Loan | | | | | | | | |
Noncash lease expense | | | 0.1 | 0.1 | 0.1 | 0.2 | 0.0 | 0.0 |
|
Change in operating assets and liabilities | | | | | | | | |
Accounts receivable | | | -0.1 | 0.9 | -0.5 | 0.5 | -0.8 | 0.0 |
Inventory | | 1.5 | 0.2 | -1.0 | -1.5 | 1.8 | -4.9 | -2.0 |
Prepaid expenses and other assets | | | 0.0 | -0.6 | -0.5 | -0.9 | 3.4 | -1.9 |
Accounts payable | | 0.0 | 0.7 | -1.7 | 0.1 | -2.5 | 3.0 | -0.6 |
Accrued expenses | | 1.0 | 0.9 | 1.1 | -1.3 | 0.6 | -0.1 | 0.7 |
Deferred revenue | | | 0.1 | 0.2 | 0.1 | 0.0 | 0.6 | -0.2 |
Net cash used in operating activities | | -5.8 | -5.9 | -8.2 | -11.6 | -8.4 | -5.7 | -10.1 |
|
Investing activities | | | | | | | | |
Proceeds from sale of property and equipment | | | | | | | 0.0 | 0.0 |
Purchase of property and equipment | | | -0.1 | 0.0 | -0.1 | -0.3 | -0.3 | |
Investments in equity securities | | | | | -1.0 | | | |
Net cash used in investing activities | | 0.0 | -0.1 | 0.0 | -1.1 | -0.3 | -0.3 | 0.0 |
|
Financing activities | | | | | | | | |
Proceeds from Newborn Escrow Account | | | | | | | | |
Redemption of Newborn shares | | | | | | | | |
Issuance costs related to reverse recapitalization and PIPE offering | | | | | | | | |
Proceeds from PIPE offering | | | | | | | | |
Repayment of Newborn sponsor loans | | | | | | | | |
Repurchase of common stock from EDF | | | | | | | | |
Newborn cash acquired | | | | | | | | |
Purchase of stock from investor | | | | | | | | |
Payment of financing costs | | | | | | | | -0.5 |
Payment of finance lease obligations | | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Proceeds from forward option put exercise | | | | | 2.0 | | | |
Proceeds from exercise of pre-funded warrants related to Direct Offering | | | 0.0 | 0.0 | | | | |
Proceeds from Direct Offering of common stock, net of offering costs | | | | 15.0 | 1.9 | | | |
Proceeds from common stock offering, net of offering costs | | | | 15.0 | 1.9 | | | |
Proceeds from exercise of stock options | | | 0.0 | 0.0 | 0.2 | | 0.6 | 0.0 |
Issuance of Redeemable Preferred Stock | | | | | | | | 3.1 |
Payment of Preferred Stock dividends | | | | | | | 0.0 | |
Net cash provided by financing activities | | | 0.0 | 15.0 | 4.0 | 0.0 | -2.4 | 2.7 |
Effect of exchange rate on cash | | | 0.1 | -0.1 | -0.2 | 0.1 | 0.0 | 0.1 |
Net increase in cash and restricted cash | | | -16.5 | | | | | |
|
Supplemental Disclosure of cash information: | | | | | | | | |
Supplemental Disclosure of Noncash Financing Activity | | | | | | | | |
Conversion of preferred stock to common stock | | | | | | | | |
Conversion of debenture and accrued interest to common shares | | | | | | | | |
Conversion of shares due to reverse recapitalization | | | | | | | | |
Issuance of common stock for merger success fee | | | | | | | | |
Non-cash merger transaction costs | | | | | | | | |
Accrued transaction costs related to reverse recapitalization | | | | | | | | |
Issuance of private warrants | | | | 15.0 | 1.9 | | | |
Forgiveness of PPP Loan | | | | | | | | |
Issuance of Stonepeak and Evolve warrants | | | | | | | | 2.6 |
Issuance of Stonepeak and Evolve options | | | | | | | | |